Stockwatch: Pandora’s Interim Analysis
Executive Summary
The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?
You may also be interested in...
Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually
When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?
Stockwatch: What Links Actimmune And Vertex’s Event Horizon?
Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.
Stockwatch: Fanning The Embers Of M&A
A drug approval at Sarepta, two acquisitions by Allergan and $15bn worth of dry powder at Takeda has prompted “biotech off to the races” commentaries by analysts and the press. This froth will probably dissipate.